Clinical and Molecular Features Associated with Biallelic Mutations in FANCD1/BRCA2

Overview

Journal J Med Genet

Specialty Genetics

Date 2006 Jul 11

PMID 16825431

Citations 117

Authors

Blanche P Alter

Philip S Rosenberg

Lawrence C Brody

Affiliations

Soon will be listed here.

Abstract

Patients with biallelic mutations in BRCA2 are in Fanconi anaemia group D1. We analysed the severity of the mutations in 27 cases, classified according to their association with breast cancer in heterozygotes, and their predicted functional effect. Twenty mutations were frameshifts or truncations, three involved splice sites, five were missense variants of unknown severity and two were benign polymorphisms. Five patients had VACTERL-H association. Leukaemia was reported in 13 patients, and solid tumours in 15; 6 patients had two or more malignancies. The cumulative probability of any malignancy was 97% by age 5.2 years. IVS7+1G-->A and IVS7+2T-->G were associated with AML, and 886delGT and 6174delT with brain tumours. However, patients with other alleles remained at very high risk of these events. Missense mutations formed a distinct cluster in a highly conserved region of the BRCA2 protein. The small group of patients with biallelic mutations in BRCA2 is distinctive in the severity of the phenotype, and early onset and high rates of leukaemia and specific solid tumours, and may comprise an extreme variant of Fanconi anaemia. Several of the alleles were not associated with cancer in presumed carriers, and thus counselling presents more uncertainties than usual.

Citing Articles

Heterozygous mutation in BRCA2 induces accelerated age-dependent decline in sperm quality with male subfertility in rats.

Motooka Y, Tanaka H, Maeda Y, Katabuchi M, Mashimo T, Toyokuni S Sci Rep. 2025; 15(1):447.

PMID: 39747609 PMC: 11696240. DOI: 10.1038/s41598-024-84184-8.

Biallelic Germline Frameshift Mutations Associated with Isolated Diminished Ovarian Reserve.

Helbling-Leclerc A, Falampin M, Heddar A, Guerrini-Rousseau L, Marchand M, Cavadias I Int J Mol Sci. 2024; 25(22).

PMID: 39596525 PMC: 11594631. DOI: 10.3390/ijms252212460.

Reduced penetrance BRCA1 and BRCA2 pathogenic variants in clinical germline genetic testing.

Pal T, Mundt E, Richardson M, Chao E, Pesaran T, Slavin T NPJ Precis Oncol. 2024; 8(1):247.

PMID: 39488595 PMC: 11531542. DOI: 10.1038/s41698-024-00741-4.

G-quadruplexes are a source of vulnerability in deficient granule cell progenitors and medulloblastoma.

Keahi D, Sanders M, Paul M, Webster A, Fang Y, Wiley T bioRxiv. 2024; .

PMID: 39091814 PMC: 11291086. DOI: 10.1101/2024.07.20.604431.

Neutropenia in Childhood-A Narrative Review and Practical Diagnostic Approach.

Katsaras G, Koutsi S, Psaroulaki E, Gouni D, Tsitsani P Hematol Rep. 2024; 16(2):375-389.

PMID: 38921186 PMC: 11203312. DOI: 10.3390/hematolrep16020038.

References

Reid S, Renwick A, Seal S, Baskcomb L, Barfoot R, Jayatilake H . Biallelic BRCA2 mutations are associated with multiple malignancies in childhood including familial Wilms tumour. J Med Genet. 2005; 42(2):147-51. PMC: 1735989. DOI: 10.1136/jmg.2004.022673. View

. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999; 91(15):1310-6. DOI: 10.1093/jnci/91.15.1310. View

Meyer S, Fergusson W, Oostra A, Medhurst A, Waisfisz Q, de Winter J . A cross-linker-sensitive myeloid leukemia cell line from a 2-year-old boy with severe Fanconi anemia and biallelic FANCD1/BRCA2 mutations. Genes Chromosomes Cancer. 2005; 42(4):404-15. DOI: 10.1002/gcc.20153. View

Taniguchi T, DAndrea A . Molecular pathogenesis of Fanconi anemia: recent progress. Blood. 2006; 107(11):4223-33. DOI: 10.1182/blood-2005-10-4240. View

Esmer C, Sanchez S, Ramos S, Molina B, Frias S, Carnevale A . DEB test for Fanconi anemia detection in patients with atypical phenotypes. Am J Med Genet A. 2003; 124A(1):35-9. DOI: 10.1002/ajmg.a.20327. View

Cox D, Hankinson S, Hunter D . No association between BRCA2 N372H and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2005; 14(5):1353-4. DOI: 10.1158/1055-9965.EPI-04-0848. View

Faivre L, Portnoi M, Pals G, Stoppa-Lyonnet D, Le Merrer M, Thauvin-Robinet C . Should chromosome breakage studies be performed in patients with VACTERL association?. Am J Med Genet A. 2005; 137(1):55-8. DOI: 10.1002/ajmg.a.30853. View

Levitus M, Waisfisz Q, Godthelp B, de Vries Y, Hussain S, Wiegant W . The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J. Nat Genet. 2005; 37(9):934-5. DOI: 10.1038/ng1625. View

Levran O, Attwooll C, Henry R, Milton K, Neveling K, Rio P . The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia. Nat Genet. 2005; 37(9):931-3. DOI: 10.1038/ng1624. View

10.

Kennedy R, DAndrea A . The Fanconi Anemia/BRCA pathway: new faces in the crowd. Genes Dev. 2005; 19(24):2925-40. DOI: 10.1101/gad.1370505. View

11.

Godthelp B, Wiegant W, Waisfisz Q, Medhurst A, Arwert F, Joenje H . Inducibility of nuclear Rad51 foci after DNA damage distinguishes all Fanconi anemia complementation groups from D1/BRCA2. Mutat Res. 2005; 594(1-2):39-48. DOI: 10.1016/j.mrfmmm.2005.07.008. View

12.

Walsh T, Casadei S, Coats K, Swisher E, Stray S, Higgins J . Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA. 2006; 295(12):1379-88. DOI: 10.1001/jama.295.12.1379. View

13.

Pyne M, Brothman A, Ward B, Pruss D, Hendrickson B, Scholl T . The BRCA2 genetic variant IVS7 + 2T-->G is a mutation. J Hum Genet. 2001; 45(6):351-7. DOI: 10.1007/s100380070007. View

14.

Szabo C, Masiello A, Ryan J, Brody L . The breast cancer information core: database design, structure, and scope. Hum Mutat. 2000; 16(2):123-31. DOI: 10.1002/1098-1004(200008)16:2<123::AID-HUMU4>3.0.CO;2-Y. View

15.

Alter B . The association between FANCD1/BRCA2 mutations and leukaemia. Br J Haematol. 2006; 133(4):446-8. DOI: 10.1111/j.1365-2141.2006.06049.x. View

16.

Garcia-Higuera I, Taniguchi T, Ganesan S, Meyn M, Timmers C, Hejna J . Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell. 2001; 7(2):249-62. DOI: 10.1016/s1097-2765(01)00173-3. View

17.

Ludwig T, Fisher P, Ganesan S, Efstratiadis A . Tumorigenesis in mice carrying a truncating Brca1 mutation. Genes Dev. 2001; 15(10):1188-93. PMC: 313794. DOI: 10.1101/gad.879201. View

18.

Joenje H, Patel K . The emerging genetic and molecular basis of Fanconi anaemia. Nat Rev Genet. 2001; 2(6):446-57. DOI: 10.1038/35076590. View

19.

Howlett N, Taniguchi T, Olson S, Cox B, Waisfisz Q, de Die-Smulders C . Biallelic inactivation of BRCA2 in Fanconi anemia. Science. 2002; 297(5581):606-9. DOI: 10.1126/science.1073834. View

20.

Alter B . Cancer in Fanconi anemia, 1927-2001. Cancer. 2003; 97(2):425-40. DOI: 10.1002/cncr.11046. View